U.S. specialist Concentra Biosciences has acquired failing Walloon biotech firm Iteos Therapeutics for $384 million, offering shareholders a swift exit and terminating ongoing clinical programs.
Concentra Biosciences, a U.S. specialist in so‑called “zombie” biotech companies, will pay $10.05 per share—totaling $384 million—to acquire Iteos Therapeutics on Nasdaq and immediately dissolve the company. Iteos decided to wind down after disappointing oncology trials earlier this year led GlaxoSmithKline to end its collaboration. At end‑March, Iteos held $624 million in cash but faced roughly $30 million in wind‑down costs, including severance for its 173 employees in Gosselies and Massachusetts.
The acquisition structure allows shareholders to receive cash now rather than through a protracted liquidation, and 80 percent of any proceeds from the sale of Iteos’s remaining early‑stage programs within six months will be distributed to them. Thereafter, all future program revenues will accrue to Concentra.
Founded in 2020 with a $200 million IPO, Iteos once traded above $40 per share. Its fall underscores the high stakes and cash burn of biotech ventures. Concentra’s model of buying underperforming firms with substantial cash reserves has become increasingly common, offering shareholders a faster payout while specialists handle the tedious dissolution process.
This deal marks the end of Iteos’s promising but ultimately unfulfilled biotech journey.
